Prolia (Denosumab) Cost in Vermont 2026: Pricing, Insurance, and Savings Options

What Does Prolia (Denosumab) Cost Without Insurance in Vermont?

The average cash-pay price for a single Prolia injection across Vermont retail pharmacies sits at approximately $1 to 500 in 2026, matching Amgen's wholesale acquisition cost. Because Prolia is dosed every six months, uninsured patients face roughly $3,000 per year before any discount programs.

That figure reflects the 60 mg/1 mL prefilled syringe. Vermont has no state-mandated drug pricing caps for biologics, so actual retail prices vary by pharmacy. Independent pharmacies in Burlington and Montpelier may charge slightly less than large chain outlets, though the difference rarely exceeds $50 to $100 per injection. The drug is classified as a biologic under the Biologics Price Competition and Innovation Act, which means no FDA-approved biosimilar for Prolia existed in the U.S. market as of early 2026. Amgen's biologic exclusivity has kept pricing stable since the drug's 2010 approval 1.

Prolia is typically administered in a physician's office or infusion center rather than dispensed at a retail pharmacy. This means the cost may appear as a medical benefit (billed under a J-code, J0897) rather than a pharmacy benefit, which changes how insurance processes the claim. Patients should confirm with their provider whether the injection will be billed under their medical or pharmacy benefit, since copay structures differ substantially between the two.

The FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every six months reduced new vertebral fractures by 68% over 36 months compared with placebo 2. That level of fracture reduction is what makes the drug's cost clinically defensible for high-risk patients, according to the American Association of Clinical Endocrinologists (AACE) 3.

Does Vermont Medicaid Cover Prolia?

Yes. Vermont Medicaid covers Prolia with prior authorization. The Vermont Department of Health Access (DVHA), which administers Green Mountain Care Medicaid, requires prescribers to document a diagnosis of osteoporosis (typically a DXA T-score of -2.5 or lower at the hip or spine) and, in many cases, evidence that the patient tried or cannot tolerate an oral bisphosphonate first.

Prior authorization requests are reviewed by the state's pharmacy benefit manager. Approval generally takes three to five business days, though urgent requests can be expedited. Once approved, PA is typically valid for 12 months and must be renewed annually. Patients on Vermont Medicaid pay $0 to $3 in copay for covered specialty drugs, depending on their specific benefit tier.

For dual-eligible beneficiaries (those with both Medicare and Medicaid), Prolia is typically covered under Medicare Part B as a physician-administered injectable. Medicare Part B covers denosumab at 80% of the Medicare-approved amount after the Part B deductible ($257 in 2025), leaving a 20% coinsurance that Medicaid may pick up as the secondary payer 4.

Vermont's Medicaid formulary also lists alendronate (generic Fosamax) and zoledronic acid (Reclast) as preferred first-line agents for osteoporosis. Prescribers requesting Prolia before a bisphosphonate trial must document clinical contraindications such as esophageal disorders, renal impairment (eGFR <35 mL/min), or documented bisphosphonate intolerance. The Endocrine Society's 2020 clinical practice guideline supports denosumab as a first-line option for patients at very high fracture risk, defined as a recent fracture within 12 months, T-score below -3.0, or high FRAX probability 5.

Which Commercial Insurance Plans Cover Prolia in Vermont?

Most major commercial insurers operating in Vermont, including Blue Cross Blue Shield of Vermont (BCBSVT), MVP Health Care, and Cigna, cover Prolia on their specialty formularies. Coverage specifics differ by plan tier.

BCBSVT, Vermont's dominant commercial carrier, lists Prolia on its specialty drug tier with step therapy requirements. Patients must typically demonstrate failure of, intolerance to, or contraindication for at least one oral bisphosphonate before Prolia is approved. Copays on specialty tiers range from $50 to $200 per injection, though many plans cap annual specialty drug out-of-pocket spending.

MVP Health Care follows a similar model. Prolia falls under the specialty pharmacy benefit, and prior authorization is required. MVP's formulary documents specify that documentation of osteoporotic fracture or a T-score of -2.5 or below is needed for approval.

Because Prolia is a physician-administered drug, it often bills through the medical benefit rather than the pharmacy benefit. This distinction matters. Under a medical benefit, the patient's cost-sharing is typically a percentage coinsurance (often 20%) rather than a flat copay. For a $1,500 drug, 20% coinsurance equals $300 per injection before any savings card is applied. Patients should ask their insurer which benefit covers J0897 before their first injection.

Vermont's Act 165, the state's health insurance regulatory framework, requires insurers to provide an external review process for coverage denials. If a PA request for Prolia is denied, patients and prescribers have the right to appeal through the insurer's internal process and, if needed, to an independent external review organization 6.

How the Amgen Assist 360 Savings Card Works in Vermont

Amgen offers the Assist 360 program, which includes a copay savings card for commercially insured patients. The card can reduce out-of-pocket costs to as little as $0 per injection, with a maximum annual benefit (typically $1,600 to $3,000 per year, depending on program terms).

Eligibility requirements are straightforward. The patient must have commercial insurance that covers Prolia. Patients insured through government programs, including Medicare, Medicaid, TRICARE, or VA benefits, do not qualify for the copay card. This is a federal anti-kickback statute restriction, not an Amgen policy choice.

To enroll, patients can register online through the Amgen Assist 360 website or call the program directly. The savings card is presented to the provider's billing office at the time of injection. If Prolia is billed under the medical benefit, the process may involve submitting a reimbursement claim after paying the coinsurance, rather than applying the card at the point of service. Patients should clarify the reimbursement workflow with the Amgen support team before their appointment.

For uninsured patients, Amgen's Safety Net Foundation offers free Prolia to qualifying individuals. Income eligibility thresholds are generally set at 500% of the federal poverty level or below. A Vermont household of one earning less than approximately $75,000 per year may qualify. Application requires proof of income and a prescription from a licensed provider.

Is Compounded Denosumab Available in Vermont?

Compounded denosumab is available in Vermont through licensed 503A compounding pharmacies. However, patients and prescribers should understand the significant differences between compounded and branded products.

Under federal law (the Drug Quality and Security Act of 2013), 503A pharmacies may compound drugs based on individual patient prescriptions. Denosumab is a monoclonal antibody, and compounding a biologic is technically complex. The Vermont Board of Pharmacy regulates 503A pharmacies within the state and requires compliance with USP 797 and USP 800 standards for sterile compounding 7.

The critical caveat: compounded denosumab is not FDA-approved. It has not undergone the same pharmacokinetic, immunogenicity, or clinical efficacy testing as Prolia. The FDA has issued multiple warnings about compounded biologics, noting that protein-based drugs are sensitive to handling, storage, and formulation conditions. A compounding error with a monoclonal antibody could produce an immunogenic product or one with reduced efficacy.

The Endocrine Society and the American Association of Clinical Endocrinologists have not endorsed compounded denosumab as an equivalent alternative to Prolia. Prescribers who choose to write for a compounded version should document informed consent and the clinical rationale.

Pricing for compounded denosumab varies, but 503A pharmacies may offer it at a substantially lower cost than the branded product. Patients considering this route should verify that the compounding pharmacy holds current Vermont Board of Pharmacy licensure and ask for certificates of analysis and potency testing results.

Can I Get Prolia Prescribed via Telehealth in Vermont?

Yes. Vermont permits telehealth prescribing of Prolia. The state's telehealth parity law (Act 5, passed in 2020 and extended) requires commercial insurers to cover telehealth visits at the same rate as in-person visits, and it allows prescribers to establish a patient-provider relationship through a synchronous video visit.

A prescriber in Vermont can evaluate bone density results, review fracture risk, and write a prescription for denosumab during a telehealth consultation. The prescription is then filled and administered at a local clinic, infusion center, or physician office. Some home health agencies in Vermont also offer at-home injection services, which can be coordinated through telehealth platforms.

Telehealth does not change the prior authorization requirements. The prescriber still must submit PA documentation to the insurer, and the patient still requires periodic DXA scans (typically every two years) to monitor treatment response. Those imaging studies must be performed in person 8.

Vermont-Specific Discount Programs and Cost Reduction Strategies

Vermont offers several pathways to reduce Prolia costs beyond the Amgen savings card.

Vermont Health Connect (ACA marketplace): Vermonters purchasing coverage through Vermont Health Connect should check whether their selected plan covers Prolia under the medical or pharmacy benefit. Silver-tier plans with cost-sharing reductions can significantly lower coinsurance for specialty drugs. The ACA's out-of-pocket maximum ($9,200 for individuals in 2025) caps annual spending regardless of how many specialty drugs a patient uses.

340B Drug Pricing Program: Federally qualified health centers (FQHCs) and certain hospitals in Vermont participate in the 340B program, which requires drug manufacturers to sell outpatient drugs at a discount to eligible healthcare organizations. Patients treated at 340B-covered entities, such as Community Health Centers of Burlington or Brattleboro Memorial Hospital, may access Prolia at reduced cost. The 340B price for Prolia is not publicly disclosed but is estimated to be 25% to 50% below wholesale acquisition cost 9.

Pharmacy benefit vs. medical benefit optimization: Some Vermont patients find it cheaper to have Prolia dispensed through a specialty pharmacy (pharmacy benefit) rather than billed as a physician-administered drug (medical benefit), or vice versa. The difference depends entirely on the patient's specific plan design. A $50 specialty copay is less than 20% of $1,500. Patients should ask their insurer to run a cost comparison under both benefit types before the first injection.

Manufacturer patient assistance: Beyond the copay card, Amgen's Safety Net Foundation provides free Prolia to eligible uninsured or underinsured patients. The application process takes approximately two to four weeks.

Discontinuation Risks and Cost Planning

Any cost discussion about Prolia must include the rebound fracture risk associated with stopping the drug. After Prolia discontinuation, bone mineral density drops rapidly, often returning to pretreatment levels within 12 to 18 months. Multiple case reports and the FREEDOM Extension trial documented an increased rate of multiple vertebral fractures in patients who stopped denosumab without transitioning to another antiresorptive agent 10.

The Endocrine Society recommends that patients who discontinue denosumab receive a bisphosphonate (oral or IV) within six months of the last Prolia injection to prevent rebound bone loss. This means that Prolia is not a drug patients should start and stop based on cost fluctuations or insurance changes. Before initiating denosumab, prescribers should discuss a long-term cost plan with the patient, including what happens if insurance coverage changes.

"Denosumab discontinuation without follow-on therapy poses a real clinical risk. Patients need a clear exit strategy before they start," stated the 2020 Endocrine Society guideline on postmenopausal osteoporosis management 5.

For Vermont patients on Medicaid who may face eligibility changes, this is particularly relevant. A lapse in Medicaid coverage could interrupt Prolia treatment. Prescribers should document the rebound risk in the medical record and discuss contingency plans, such as a single zoledronic acid infusion ($300 to $500 via Medicare Part B), as a bridge if coverage lapses.

Dr. Robert Adler, former Chief of Endocrinology at the VA Medical Center in Richmond and a co-author of the AACE osteoporosis guidelines, has noted: "The decision to start denosumab should include a commitment to continuity. This is not a medication you take for a year and reassess casually" 3.